Answers are grounded in this paper and cite their sources.
Background: Adverse drug reactions (ADRs) represent a significant global health concern, yet under-reporting persists as a critical pharmacovigilance challenge in developing countries, necessitating evaluation of prescribers' knowledge, attitude, and practices (KAPs) regarding ADR reporting.Objective: To evaluate the KAPs of ADR reporting among prescribers at a Tertiary Care Teaching Hospital in Eastern India.Materials and methods: A cross-sectional, questionnaire-based study was conducted at MGM Medical College and LSK Hospital, Kishanganj, Bihar, from January to February 2024.A validated 19-item KAP questionnaire was administered to prescribers, including faculty, resident doctors, and interns.Knowledge was scored out of 10 points and categorized as poor (0-3), average (4-6), or good (7-10).Data were analyzed using SPSS version 21, with the Chi-square test for categorical variables and appropriate non-parametric tests for continuous data.Results and analysis: Of 274 distributed questionnaires, 168 were returned (61.31% response rate), comprising 43 faculty (25.60%), 74 resident doctors (44.05%), and 51 interns (30.36%).Mean knowledge scores were moderate overall (6.07 ± 1.531), with faculty scoring highest (6.59 ± 1.329), followed by resident doctors (6.07 ± 1.531) and interns (5.62 ± 1.186) (p = 0.002).While 93-99% correctly defined pharmacovigilance, significant knowledge gaps existed regarding banned drugs (p < 0.0001) and institutional monitoring centers (57-72% unaware).Attitudes were predominantly positive, with 90-100% acknowledging reporting necessity, though only 16-60% viewed it as a professional obligation.Most critically, actual reporting practices were severely deficient, with only 16-18% having submitted ADR forms, 69-77% lacking access to reporting forms, and 80-92% never receiving formal training.Conclusion: Despite moderate knowledge and positive attitudes, prescribers demonstrated critically deficient ADR reporting practices due to systemic barriers, including lack of procedural knowledge, limited infrastructure access, and minimal training.Multi-faceted interventions addressing both individual knowledge deficits and institutional barriers are urgently needed to enhance pharmacovigilance and patient safety.
No takes yet. Share an insight, caveat, or question.
Bhattacharjee et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: